High-Purity Gimeracil (CAS 103766-25-2): Pharmaceutical Intermediate Manufacturer & Supplier in China

Discover high-quality Gimeracil (CAS 103766-25-2), a crucial dihydropyrimidine dehydrogenase (DPD) inhibitor for advanced cancer therapies. As a leading manufacturer and supplier in China, we offer competitive pricing and reliable supply for your research and pharmaceutical formulation needs.

Get a Quote & Sample

Key Advantages of Sourcing Gimeracil from Us

Exceptional Purity and Quality

Our Gimeracil (CAS 103766-25-2) meets stringent quality standards, ensuring 99% minimum purity for reliable performance in demanding applications. We are a reputable supplier you can trust for your pharmaceutical intermediate needs.

Enhanced Therapeutic Efficacy

As a potent dihydropyrimidine dehydrogenase (DPD) inhibitor, Gimeracil plays a vital role in prolonging the circulating concentrations of pyrimidine-based chemotherapeutics, thereby improving treatment outcomes.

Cost-Effective Bulk Purchasing

We offer competitive pricing for bulk orders of Gimeracil, making it an economically viable option for large-scale pharmaceutical research and production. Contact us to buy Gimeracil at the best price.

Applications of Gimeracil in Pharmaceutical Research

Oncology Drug Formulations

Gimeracil is a key component in advanced cancer therapies, often used in combination with 5-FU to enhance its effectiveness by inhibiting DPD-mediated degradation.

DNA Repair Inhibition

The compound acts as a radiosensitizer by inhibiting homologous recombination in DNA double strand break repair, a crucial aspect of cancer treatment strategies.

Pharmacokinetic Modulation

For researchers and formulators, Gimeracil helps to modulate the pharmacokinetics of pyrimidine analogs, extending their therapeutic window and improving patient outcomes.

Advanced Cancer Research

Utilize high-quality Gimeracil for cutting-edge research in cancer metabolism, drug development, and combination therapy strategies. Purchase Gimeracil from a leading Chinese supplier.